Ruth Plummer is Professor of Experimental Cancer Medicine at the Newcastle University and Director of the Sir Bobby Robson Cancer Trials Research Centre. She leads the Newcastle Experimental Cancer Medicine Centre and also the CRUK Newcastle Cancer Centre. Her research interests are in the field of DNA repair and early phase clinical trials of novel agents, taking the first in class PARP, ATR and MCT1 inhibitors into the clinic.
Nationally, Ruth chairs the MRC Experimental Medicine Panel, and sits as a member of Cancer Research UK’s Clinical Research Committee and Research Careers Committee. She is also a member of the MRC Precision Medicine Group and the NIHR EME Committee. She was elected a Fellow of the Academy of Medical Sciences in 2018 for her work developing PARP inhibitors as novel cancer treatments, and in 2021 was awarded the ESMO-TAT Lifetime Achievement Award for her work in early phase cancer clinical trials.
